Results 31 to 40 of about 82,297 (250)
Journal of Lipid Research, 2006 Statins do not always decrease coronary heart disease mortality, which was speculated based on increased serum plant sterols observed during statin treatment.
Jogchum Plat +4 more
doaj +1 more source
A mechanistic study on the phototoxicity of atorvastatin: singlet oxygen generation by a phenanthrene-like photoproduct [PDF]
, 2009 Atorvastatin calcium (ATV) is one of the most frequently prescribed drugs worldwide. Among the adverse effects observed for this lipid-lowering agent, clinical cases of cutaneous adverse reactions have been reported and associated with photosensitivity ...
IESCE, MARIA ROSARIA +4 more
core +1 more source
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2019 The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs).
Bridget L. Morse +9 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Dyslipidemia due to renal insufficiency is a common complication in patients with chronic kidney diseases (CKD), and a major risk factor for the development of cardiovascular events.
Zebin Jiang +13 more
doaj +1 more source
Frontiers in Pharmacology, 2015 Several clinical trials have substantiated the efficacy of the co-administration of statins like atorvastatin and fibrates. Without information currently available about the interaction between the two drugs, a pharmacokinetic study was conducted to ...
Omar ePatiño-Rodríguez +9 more
doaj +1 more source
Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers
Advanced Functional Materials, EarlyView.A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley +1 more source
Drugs - Real World OutcomesIntroduction High levels of low-density lipoprotein-cholesterol (LDL) is a major risk factor for cardiovascular diseases. While treatment with atorvastatin is beneficial, the original atorvastatin may be cost prohibitive to some patients.
Panisa Manasirisuk +4 more
doaj +1 more source
Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
Pharmaceuticals, 2022 The interaction between statins and omega-3 fatty acids remains controversial. The aim of this phase 1 trial was to evaluate the pharmacokinetics of drug-drug interaction between atorvastatin and omega-3 fatty acids.
Jae Hoon Kim +10 more
doaj +1 more source
Statin therapy in critical illness : an international survey of intensive care physicians' opinions, attitudes and practice [PDF]
, 2012 Background Pleotropic effects of statins on inflammation are hypothesised to attenuate the severity of and possibly prevent the occurrence of the host inflammatory response to pathogen and infection-related acute organ failure.
Di Gangi, Stefania +6 more
core +1 more source